Early test for copycat allergy drug halted after one person
NCT ID NCT04361812
Summary
This early-stage study aimed to see if a new drug called HS632 acts similarly in the body to an existing allergy medication, omalizumab (Xolair®). It involved giving a single injection to healthy male volunteers to compare how the drugs are processed and their safety. The trial was terminated early after enrolling only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIMILARITY OF PHARMACOKINETICS AND SAFETY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Peng
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.